Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 92Breast Neoplasms 69Prostatic Neoplasms 33Triple Negative Breast Neoplasms 32Neoplasms 26Fallopian Tube Neoplasms 25Neoplasm Metastasis 21Endometrial Neoplasms 19Pancreatic Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Urothelial Cancer × olaparib × Clear all
NCT03448718 2023-11-22

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Hoosier Cancer Research Network

Phase 2 Completed
19 enrolled 9 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡